No prior CVD group (n = 1013) | Prior CVD group (n = 4996) | |||||
---|---|---|---|---|---|---|
Odds ratio | 95 % CI | P value | Odds ratio | 95 % CI | P value | |
Region (Europe as reference group) | 1.662 | 1.150; 2.402 | 0.007 | 1.314 | 1.136; 1.520 | <0.001 |
Age (per year) | 0.959 | 0.928; 0.990 | 0.009 | 0.992 | 0.982; 1.002 | 0.115 |
Sex (male as reference group) | 0.823 | 0.341; 1.707 | 0.641 | 1.070 | 0.901; 1.270 | 0.438 |
Diabetes duration (per year) | 1.020 | 0.998; 1.042 | 0.082 | 1.003 | 0.995; 1.012 | 0.472 |
Race (white as reference group) | ||||||
Asian | 1.758 | 0.457; 6.795 | 0.880 | 0.483; 1.560 | 0.064 | |
Black | 1.070 | 0.517; 2.318 | 0.604 | 0.724 | 0.551; 0.946 | |
Other | 0.442 | 0.063; 1.987 | 0.621 | 0.304; 1.189 | ||
BMI (18–25, reference group) ( kg/m2) | ||||||
25–30 | 1.217 | 0.577;2.677 | 0.889 | 0.655; 1.212 | ||
30–35 | 0.913 | 0.436;1.998 | 0.009 | 0.793 | 0.587; 1.077 | 0.008 |
35–40 | 0.511 | 0.229;1.177 | 0.693 | 0.503; 0.957 | ||
>40 | 0.650 | 0.283;1.533 | 0.623 | 0.442; 0.879 | ||
Number of antihypertensive medications | ||||||
0 (reference group) | ||||||
1 | 1.142 | 0.698; 1.897 | 0.918 | 0.693; 1.221 | ||
2 | 0.716 | 0.415; 1.244 | 0.096 | 1.010 | 0.772; 1.326 | <0.001 |
3 | 0.650 | 0.333; 1.256 | 0.648 | 0.477; 0.881 | ||
4 | 1.024 | 0.360; 2.670 | 0.646 | 0.424;0.975 | ||
Creatinine, per umol/L | 0.986 | 0.942; 1.021 | 0.488 | 1.004 | 1.000; 1.008 | 0.058 |
ACR, per mg/mmol | 0.992 | 0.983; 0.999 | 0.013 | 0.994 | 0.992; 0.996 | <0.001 |
eGFR,per mL/min/1.73 m2 | 0.985 | 0.956; 1.007 | 0.239 | 0.998 | 0.992; 1.003 | 0.334 |
Micro-albuminuria | 0.895 | 0.628; 1.275 | 0.538 | 0.947 | 0.774; 1.155 | 0.592 |
Macro-albuminuria | 0.918 | 0.507; 1.635 | 0.775 | 1.562 | 1.060; 2.287 | 0.024 |